Abstract submitters may participate in the application process for the following awards:

DOP Awards

The winners of the Top 15 DOP awards are:

DOP006: Long term maintenance treatment with vedolizumab in pediatric IBD: a three-year follow-up of the prospective multicenter VEDOKIDS study - Dan Turner, Jerusalem, Israel

DOP017: Infliximab induction fails to reach targets in Perianal Fistulizing Crohn’s Disease: first results from the ATLANTIC study - Lieven Mulders, Amsterdam, The Netherlands

DOP027: Caudovirales may trigger molecular mimicry mechanisms in Crohn’s Disease - Carmela Errico, Milan, Italy

DOP030: Mucosal deficiency of mitochondria-driven humoral immunity is linked to Crohn’s Disease - Annika Raschdorf, Lübeck, Germany

DOP044: Active disease on intestinal ultrasound in pregnancy is associated with an increased risk of adverse obstetric and neonatal outcomes: an international multi-centre prospective cohort study. - Emma Flanagan, Fitzroy, Australia

DOP053: Efficacy of appendectomy in inducing remission in moderate-to-severe ulcerative colitis: preliminary one year results of a multicentre prospective cohort study (COSTA) - Eva Visser, Amsterdam, The Netherlands

DOP056: TDM-Based Dose-Intensification of Infliximab is not Superior to Standard Dosing in Patients with Acute Severe Ulcerative Colitis: Results from the TITRATE Study - Joep Van Oostrom, Amsterdam, The Netherlands

DOP068: Vedolizumab counteracts Parkinson’s disease-related brain pathology driven by gut-primed IBD T cells - Elizaveta Gerasimova, Erlangen, Germany

DOP076: Translational and preclinical study validating anterior gradient 2 as a novel epithelial therapeutic target in Inflammatory Bowel Disease (IBD) involved in inflammation, fibrosis, and intestinal barrier integrity - Xavier Tretón, Neuilly, France

DOP084: Development of a core outcome set for Inflammatory Bowel Disease patients with stomas - Lakshman Kumar, Dublin, Ireland

DOP097: Emulsifier restriction is an effective therapy for active Crohn’s disease: the ADDapt trial - a multi-centre, randomised, double-blind, placebo-controlled, re-supplementation trial in 154 patients - Aaron Bancil, London, United Kingdom

DOP106: Geographic disparities in Healthcare Utilisation in people with inflammatory bowel disease, Crohn’s Colitis Cure Data Insights Program - Jane Mary Andrews, Sydney, Australia

DOP109: A necroptotic-to-apoptotic signaling axis underlies inflammatory bowel disease - Britt Christensen, Parkville, Australia

DOP126: Circulating neutrophils exhibit distinct transcriptional and maturity changes in CD and UC that relate to pathogenic Th1/17 CD4+ memory T cell responses - M. Fernanda Pascutti, Rotterdam, The Netherlands

DOP135: Patient-specific regulatory network rewiring in Inflammatory Bowel Disease: How genetic polymorphisms divert incoming signals and contribute to disease pathogenesis - John P Thomas, London, United Kingdom

Best Investigator-Initiated Study (IIS) report submitted - IIS Abstract Award

The winners are:

OP16: Koianka Trencheva, New York, United States

OP35: Peter Bossuyt, Bonheiden, Belgium 

The Clinical Research Committee of ECCO (ClinCom) wants to stimulate the development of high-quality Investigator-Initiated Studies (IIS) in IBD and to improve the quality of IBD clinical studies in Europe through education. In 2025, awards will be given to the 2 best congress abstracts reporting on clinical studies set up by investigators (preferably multi-centre) submitted for the ECCO Congress. Note: Studies conducted by industry will not be eligible for this award.

Responsible Committee: Clinical Research Committee of ECCO (ClinCom)
Prize: Free registration for the ECCO Congress 2026
Number of awards: 2
Who can apply: ECCO Members reporting on clinical studies set up by investigators in their abstracts. Note: ECCO Membership fee 2025 must be paid up until the abstract submission deadline.
How to apply:

• In case you are not an ECCO Member yet please register for ECCO Membership 2025
• Log in to the ECCO'25 Abstract submission system
• At the beginning of the submission process please indicate if your abstract is qualified for the IIS Abstract Award
• Please pay careful attention to the general guidelines for abstract submission
• Upload your abstract for the ECCO Congress 2025
• Notification of the author in the beginning of December 2024
• Announcement at the ECCO'25 Congress

Y-ECCO Abstract Award

The winners are:

OP01: Arno R. Bourgonje, New York, United States

OP07: Lauranne Derikx, Rotterdam, The Netherlands

OP19: Aleksejs Sazonovs, Copenhagen, Denmark

OP24: Victoria Gudiño, Barcelona, Spain

DOP006: Dan Turner, Jerusalem, Israel

The Young ECCO (Y-ECCO) encourages Y-ECCO Members to submit their abstract and share their research with the ECCO Community. Awards will be given to the 5 best-ranked abstracts along with a free congress registration for the following year.

Responsible Committee: Young-ECCO (Y-ECCO)
Prize: Free registration for the ECCO Congress 2026
Number of awards: 5
Who can apply: Y-ECCO Members (below 35 years of age or still in training). Note: ECCO Membership fee 2025 must be paid up until the abstract submission deadline.
How to apply:

• In case you are not an ECCO Member yet please register for ECCO Membership 2025
• Log in to the ECCO'25 Abstract submission system
• At the beginning of the submission process please indicate if your abstract is qualified for the Y-ECCO Abstract Award
• Please pay careful attention to the general guidelines for abstract submission
• Upload your abstract for the ECCO Congress 2025
• Notification of the author in the beginning of December 2024
• Announcement at the ECCO'25 Congress